Myriad Submits First PMA Module for BRACAnalysis CDx

Apr 07, 2014

NEW YORK (GenomeWeb News) ─ Myriad Genetics has submitted to the US Food and Drug Administration the first module of its premarket approval application for BRACAnalysis as a companion test for AstraZeneca's breast cancer PARP inhibitor olaparib.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

This Week in Nature

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Its Own Version

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

Just the Train Going By

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

New Technique a 'Go'

The House of Lords in the UK approves a bill to allow mitochondrial donation.

Featured White Papers

Reducing the variability of pre-analytical handling of biological samples

Main menu